Patents by Inventor Nigel H. Greig
Nigel H. Greig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11771657Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.Type: GrantFiled: November 9, 2021Date of Patent: October 3, 2023Assignees: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Dong Seok Kim, Hee Kyung Kim, Nigel H. Greig
-
Patent number: 11440880Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: October 29, 2020Date of Patent: September 13, 2022Assignees: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Publication number: 20220265563Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.Type: ApplicationFiled: November 9, 2021Publication date: August 25, 2022Inventors: Dong Seok Kim, Hee Kyung Kim, Nigel H. Greig
-
Patent number: 11273130Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.Type: GrantFiled: October 20, 2017Date of Patent: March 15, 2022Assignees: The United States, as represented by the Secretary Department of Health and Human Services, Peptron, Inc.Inventors: Dong Seok Kim, Hee Kyung Kim, Nigel H. Greig
-
Patent number: 10941187Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: GrantFiled: August 27, 2014Date of Patent: March 9, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
-
Publication number: 20210047267Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: ApplicationFiled: October 29, 2020Publication date: February 18, 2021Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 10836721Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: June 24, 2020Date of Patent: November 17, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Publication number: 20200325102Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: ApplicationFiled: June 24, 2020Publication date: October 15, 2020Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 10730835Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: September 29, 2016Date of Patent: August 4, 2020Assignees: The United States of America, as represented by the Secretary, Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Publication number: 20200046645Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.Type: ApplicationFiled: October 20, 2017Publication date: February 13, 2020Inventors: Dong Seok Kim, Hee Kyung Kim, Nigel H. Greig
-
Patent number: 10220028Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: March 13, 2017Date of Patent: March 5, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20180273472Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: ApplicationFiled: September 29, 2016Publication date: September 27, 2018Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Publication number: 20170182022Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Patent number: 9623020Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: June 22, 2015Date of Patent: April 18, 2017Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20150359784Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: ApplicationFiled: June 22, 2015Publication date: December 17, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20150072930Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: ApplicationFiled: August 27, 2014Publication date: March 12, 2015Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
-
Patent number: 8927725Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: December 2, 2011Date of Patent: January 6, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20140309436Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: ApplicationFiled: June 25, 2014Publication date: October 16, 2014Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 8853253Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: GrantFiled: October 10, 2012Date of Patent: October 7, 2014Assignee: P2D, Inc.Inventors: Nigel H. Greig, Harold Holloway, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 8853160Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: GrantFiled: August 24, 2012Date of Patent: October 7, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry